ALISO VIEJO, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the company's CEO, Ronald Andrews, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show.
The interview gives viewers an overview of the company, and the significance of the company's latest press release.
To view the clip in its entirety, visit:
Ask Ronald Andrews a question, post a comment on his personal page, and join his financial social network today at:
About Clarient, Inc.:
Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care, and accelerate the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics partner company. http://www.clarientinc.com.
About WallStreet Direct, Inc.
WallStreet Direct, Inc. operates WallSt.net (http://www.wallst.net), a
leading source of up-to-the-minute business news, comprehensive financial
tools and original multimedia content for the investment community. In
addition to WallSt.net, WallStreet Direct owns and operates WallStRadio
(http://radio.wallst.net), an online hub for business podcasts from
well-known business news personalities and publishers, and WallStTV
(http://tv.wallst.net), a hub for business and finance video content. We
have received one thousand seven hundred dollars from Clarient, Inc. in
2007 for media and advertising services, and an additional two hundred
eighty dollars from Clarient, Inc. for the dissemination of this press
release. To read our full disclaimer, and for a complete list of our
advertisers, and advertising relationships, visit
Contact: WallStreet Direct, Inc.
|SOURCE Clarient, Inc.; WallStreet Direct, Inc.|
Copyright©2008 PR Newswire.
All rights reserved